Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.26 USD | -3.20% | -37.88% | -46.94% |
05-08 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
05-08 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.94% | 660M | |
+31.08% | 695B | |
+26.51% | 568B | |
-4.62% | 361B | |
+19.71% | 330B | |
+3.92% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.75% | 168B |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- EyePoint Pharmaceuticals Grants Betta Pharmaceuticals Rights to Commercialize Chronic Eye Disorder Treatment in China